FDA Medical Device Master Files (MAF): Types, LOA & Sourcing Strategy (2026)

Executive Summary & Direct Decision Brief

Scenario Question: We are a component supplier (or medical device OEM) wanting to protect proprietary material formulations, contract manufacturing processes, or biocompatibility data during FDA premarket review. How does an FDA Medical Device Master File (MAF) work, and how is it cross-referenced without revealing trade secrets to the device sponsor?

Direct Answer: An FDA Medical Device Master File (MAF)—governed by 21 CFR 814.20(c) (the master-file incorporation-by-reference provision of the PMA rule, with "master file" defined at 21 CFR 814.3(d)) and Center for Devices and Radiological Health (CDRH) policy—is a confidential reference document submitted directly to the FDA by a supplier, contract manufacturer, or material vendor. It allows CDRH reviewers to evaluate proprietary technical data (such as raw material chemistry, sterilization parameters, specialized component tooling, or toxicological testing) in support of an OEM sponsor's premarket submission (510(k), PMA, De Novo, or IDE) without disclosing trade secrets to the sponsor or the public.

To grant FDA permission to inspect the confidential file during review, the MAF holder issues a Letter of Authorization (LOA) specifying the MAF number, the sponsor name, and the submission scope. Unlike CDER Drug Master Files (DMFs) under GDUFA, CDRH Medical Device Master Files do not currently incur FDA user fees for submission or annual maintenance.

---

1. What is an FDA Medical Device Master File (MAF) and Why Is It Used?

In medical device manufacturing, original equipment manufacturers (OEMs) frequently rely on specialized component suppliers, raw material synthesis vendors, contract sterilizers, and contract manufacturing organizations (CMOs). These upstream partners often spend millions of dollars developing proprietary technologies—such as novel bioabsorbable polymers, high-precision ceramic bearings, specialized anti-thrombogenic coatings, or automated assembly workflows.

When an OEM submits a premarket notification (510(k)), Premarket Approval (PMA), De Novo classification request, or Investigational Device Exemption (IDE) to FDA CDRH, the agency requires granular technical data to establish device safety, effectiveness, or substantial equivalence. However, requiring suppliers to share proprietary synthesis steps or trade-secret formulations with the OEM would expose critical IP to commercial risk.

+-----------------------------------------------------------------------------------+
|                            THE MAF CONFIDENTIALITY BRIDGE                         |
|                                                                                   |
|   +-------------------+      Confidential MAF Data     +----------------------+   |
|   |  Component/Material| -----------------------------> |      FDA CDRH        |   |
|   |      Supplier     |      (21 CFR 814.20(c))        |   Review Branch      |   |
|   +-------------------+                                +----------------------+   |
|             |                                                     ^               |
|             | Issues Letter of Authorization (LOA)                | References    |
|             v                                                     | Confidential  |
|   +-------------------+      eSTAR 510(k) / PMA Submission        | File via LOA  |
|   |    Medical Device | ------------------------------------------+               |
|   |      OEM Sponsor  |       (Includes LOA Reference)                            |
|   +-------------------+                                                           |
+-----------------------------------------------------------------------------------+

The Medical Device Master File (MAF) acts as a regulatory bridge:

1. IP Protection for Suppliers: Vendors submit detailed proprietary formulations, manufacturing parameters, or toxicological data directly to FDA. The contents remain strictly confidential between the vendor and CDRH.
2. Review Expediting for OEMs: Device sponsors include the supplier's Letter of Authorization (LOA) in their eSTAR 510(k) or PMA package, allowing FDA reviewers to evaluate the supplier's confidential data directly.
3. Premarket Efficiency: A single MAF can support dozens of different OEM device submissions across multiple sponsors without duplicating data filings.

Key Regulatory Status: MAF Approval vs. Review

A common misconception among suppliers is that filing an MAF yields an "FDA approval" or "FDA clearance" badge for their raw material or component.

Important Regulatory Fact: FDA CDRH does not formally approve, clear, or endorse a Medical Device Master File upon submission. When an MAF is filed, FDA Document Control Center (DCC) performs an administrative review, assigns an MAF reference number (e.g., MAF-XXXX), and places the document in a confidential archive. FDA reviewers inspect and evaluate the scientific content of the MAF only when a device sponsor cross-references that MAF number in an active premarket submission (510(k), PMA, De Novo, or IDE) accompanied by a valid Letter of Authorization (LOA).

---

2. What Functional Categories Do Medical Device Master Files Cover?

A frequent point of confusion worth clearing up first: FDA does not assign numbered "Type I–V" labels to device master files. That Type I–V numbering belongs to CDER Drug Master Files (DMFs), not to CDRH MAFs. For CDRH device master files, FDA's Device Master Files page groups submissions by the function the confidential data serves, under the heading "Types of MAFs and Their Functions." A single MAF commonly spans several of these functional groupings at once. The recognized functions are:

MAF Function (per FDA)	Subject Matter & Scope	Typical Submitters	Example Contents & Technical Data
Facilities, manufacturing procedures & controls	Site operations, cleanroom and production controls, operating procedures	Contract Manufacturers (CMOs), Cleanroom Operators, Testing Facilities	Site layouts, environmental monitoring procedures, HVAC specifications, cleanroom ISO class validations, personnel training programs, and master equipment lists.
Materials, chemicals & subassemblies	Synthesis, formulation, purification, and specifications for materials (e.g., an alloy or plastic) or device subassemblies	Polymer Synthesis Companies, Alloy Mills, Sensor Vendors, Tubing Extruders	Exact resin chemical characterization, raw material master formulations, monomer ratios, trace element limits, CAD drawings, compounding parameters, and component specifications.
Packaging materials	Primary and secondary packaging components and sterile-barrier materials	Packaging Converter Plants, Pouch/Film Manufacturers	Pouch film formulations, seal peel-strength data, and sterile-barrier system specifications.
Contract packaging & other manufacturing (incl. sterilization)	Contract sterilization, packaging, and other outsourced manufacturing steps	Contract Sterilizers (EtO, Gamma, E-beam, VHP), Contract Packers	Ethylene Oxide sterilization cycle validation protocols (ISO 11135), sublethal dose studies, aeration curves, radiation dose maps (ISO 11137), pouch sealing parameters, and shelf-life stability data.
Nonclinical study data	Toxicology, biocompatibility, and other nonclinical study packages	Independent Testing Laboratories, Material Manufacturers, Contract Research Orgs	ISO 10993 cytotoxicity, sensitization, irritation, systemic toxicity, genotoxicity reports, chemical extractables/leachables (E&L) characterization, and extractable risk assessments.
Clinical study data	Clinical study results and proprietary device data	OEM Technology Licensors, Software Vendors, Clinical Trial Collaborators	Human clinical trial datasets, proprietary software algorithms (SaMD modules), companion diagnostic validation data, and platform device characterization.

Deep Dive: Materials and Sterilization MAFs Dominate Practice

In industry practice, the vast majority of active MAFs filed with CDRH fall under the materials/subassemblies and contract manufacturing/sterilization functions:

• Materials MAFs: Medical-grade resin suppliers (e.g., PEEK, implantable silicone, polyurethane, Nitinol alloy, bioresorbable PLA/PGA) file materials MAFs to protect proprietary monomer proportions and additive packages (such as radiopacifiers or colorants). OEMs purchasing these materials reference the materials MAF to fulfill FDA's raw material characterization requirements without forcing the resin vendor to reveal secret chemical recipes.
• Sterilization MAFs: Contract EtO sterilizers file sterilization/contract-manufacturing MAFs detailing proprietary multi-chamber cycle parameters, gas concentration dynamics, and bioburden resistance data. This enables device sponsors to demonstrate sterile barrier compliance without repeating full chamber validation for every minor product variant.

---

3. How Does a Letter of Authorization (LOA) Work?

The Letter of Authorization (LOA)—sometimes referred to as a Letter of Access—is the legal and administrative key that connects a supplier's confidential MAF to an OEM's premarket device submission. Without a valid LOA submitted in the OEM's eSTAR package, FDA reviewers are legally barred from inspecting the MAF on the sponsor's behalf.

+------------------------------------------------------------------------------------+
|                       LETTER OF AUTHORIZATION (LOA) WORKFLOW                       |
|                                                                                    |
|  [Step 1: MAF Creation]                                                            |
|  Supplier submits MAF to FDA CDRH DCC  --->  FDA assigns MAF Number (e.g. MAF-1234)|
|                                                                                    |
|  [Step 2: Commercial Agreement]                                                    |
|  OEM purchases supplier component/material & requests regulatory authorization    |
|                                                                                    |
|  [Step 3: LOA Issuance]                                                            |
|  Supplier issues formal signed LOA to OEM specifying MAF-1234 & Submission Scope   |
|                                                                                    |
|  [Step 4: eSTAR Filing]                                                            |
|  OEM attaches LOA in eSTAR 510(k)/PMA submission package under Supplier Section    |
|                                                                                    |
|  [Step 5: FDA Review Cross-Reference]                                              |
|  FDA Lead Reviewer uses LOA to pull MAF-1234 from CDRH archive & verifies data     |
+------------------------------------------------------------------------------------+

Essential Elements of an FDA-Compliant LOA

To ensure immediate acceptance by FDA CDRH Document Control Center during premarket screening, the LOA must be printed on the MAF holder's official company letterhead, signed by an authorized corporate representative, and contain the following mandatory data fields:

1. Date of Authorization: The exact date the letter is executed.
2. MAF Reference Number: The official FDA-assigned MAF number (and, where useful, the functional scope — facilities, materials, packaging, sterilization, nonclinical, or clinical data).
3. MAF Holder Information: Full corporate name, physical address, contact person, phone number, and email.
4. Authorized Device Sponsor (OEM): Legal name and corporate address of the OEM permitted to reference the file.
5. Authorized Submission & Product Name: The specific device trade name, model numbers, and submission type (e.g., "510(k) submission for the Apex Vascular Stent Delivery System").
6. Scope of Authorization: Specific sections or data blocks within the MAF that FDA is authorized to review (e.g., "All biocompatibility testing under Section 4 and EtO sterilization validation under Section 6").
7. Statement of Access Commitment: Explicit language authorizing FDA CDRH personnel to inspect and cross-reference the identified MAF contents in support of the named sponsor's submission.

# SAMPLE LOA AUTHORIZATION CLAUSE

"We, [Supplier Corporate Name], hereby authorize the Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) to reference and review our Medical Device Master File, MAF-XXXXX (covering resin chemical characterization and ISO 10993 biocompatibility data), in support of the premarket notification (510(k)) submission submitted by [OEM Sponsor Name] for the [Device Trade Name].

This authorization extends to all chemical characterization data, ISO 10993 cytotoxicity test reports, and raw material specifications contained in Sections 2 through 5 of MAF-XXXXX. This letter grants permission to FDA CDRH review staff only and does not authorize [OEM Sponsor Name] or any third party to inspect the confidential contents of MAF-XXXXX."

Detailed Structure of a Materials MAF Dossier

To ensure suppliers understand what technical depth FDA expects inside a materials-and-subassemblies MAF, the following table details the standard technical sections required for a medical-grade polymer or implantable alloy filing:

Dossier Section	Regulatory Focus	Technical Content Required by FDA CDRH
Section 1: General Product Information	Material Identification	Trade names, chemical family, CAS numbers, physical state, intended medical applications (e.g., short-term mucosal contact vs. permanent cardiovascular implant).
Section 2: Raw Material Synthesis & Composition	Trade-Secret Chemistry	Monomer ratios, catalyst residues, polymerization inhibitors, plasticizers, anti-oxidants, radiopacifiers (barium sulfate, bismuth subcarbonate), and trace element thresholds.
Section 3: Manufacturing & Compounding Control	Process Repeatability	Compounding parameters, extrusion temperatures, pelletization specs, lot size definitions, equipment cleaning protocols, and in-process quality controls (IPQC).
Section 4: Material Specifications & CoA	Release Criteria	Certificate of Analysis acceptance limits: melt flow index (MFI), intrinsic viscosity (IV), tensile strength, elongation at break, residual monomer ppm, moisture content.
Section 5: Biocompatibility Evaluation (ISO 10993)	Biological Safety	Full ISO 10993 test battery: cytotoxicity (10993-5), sensitization (10993-10), irritation (10993-23), systemic toxicity (10993-11), genotoxicity (10993-3), and chemical extractables/leachables (E&L under 10993-18).
Section 6: Chemical Characterization & E&L	Toxicological Risk	GC-MS, LC-MS, and ICP-MS non-targeted screening data, extractable profile under polar/non-polar solvents, and toxicological threshold of evaluation (TTE) risk assessments.
Section 7: Stability & Aging Data	Shelf-Life Support	Real-time and accelerated aging data (ASTM F1980) demonstrating physical, chemical, and biological stability over time.

---

Recommended Reading

FDA Pediatric Medical Device Regulation: Pathways, Section 515A, and Waivers

Regulatory Clinical Evidence2026-07-26 · 18 min read

4. MAF vs. DMF vs. DMR: Clearing Up Industry Confusion

Regulatory managers and quality engineers often confuse Medical Device Master Files (MAF) with Drug Master Files (DMF) or Quality System Device Master Records (DMR). While all three use similar acronyms, their regulatory oversight, statutory basis, and operational roles differ fundamentally.

Attribute / Feature	CDRH Medical Device Master File (MAF)	CDER Drug Master File (DMF)	Quality System Device Master Record (DMR)
Governing Regulation	21 CFR 814.20(c) (term defined at 814.3(d))	21 CFR § 314.420	21 CFR § 820.181 (QMSR / ISO 13485)
Primary FDA Center	CDRH (Devices) / CBER (Biologics)	CDER (Drugs) / CBER (Biologics)	CDRH (Enforcement via QMS Inspection)
Owner / Holder	Upstream Supplier / Vendor / CMO	Active Pharmaceutical Ingredient (API) Vendor	Medical Device OEM / Legal Manufacturer
Purpose & Function	Confidential reference for device premarket review (510k, PMA, IDE)	Confidential reference for drug applications (NDA, ANDA, IND)	Total technical & manufacturing blueprint for finished device
FDA User Fees	Zero User Fees (No MDUFA fee for MAF filing)	GDUFA Fees Apply (Type II API DMFs require fee under GDUFA)	None (Internal QMS document required by law)
Public Visibility	Confidential (FDA assigns number; no public database)	Published List (FDA publishes quarterly public DMF list)	Internal QMS File (Inspected during FDA QSIT / QMSR audits)
Annual Updates	Mandatory (Annual report to maintain active status)	Mandatory (Annual report to maintain active status)	Dynamic change control under QMS procedures

Why the Distinction Matters for Combination Products

For sponsors developing drug-device combination products (such as prefilled syringes, drug-eluting stents, or auto-injectors), understanding the difference between CDRH MAFs and CDER DMFs is critical:

• If the primary mode of action (PMOA) is device-led (CDRH jurisdiction), component suppliers file CDRH MAFs under 21 CFR Part 814.
• If the PMOA is drug-led (CDER jurisdiction), chemical API and container-closure vendors file CDER DMFs under 21 CFR § 314.420.
• Mixing up CDRH MAF and CDER DMF submission formats can cause administrative refusal during eSTAR or eCTD gateway intake.

---

5. Step-by-Step Requirements for Filing and Maintaining an MAF

Filing a Medical Device Master File requires structured technical preparation, eCOPY/eSub submission formatting, and ongoing annual maintenance.

+------------------------------------------------------------------------------------+
|                         MAF LIFECYCLE MANAGEMENT STAGES                            |
|                                                                                    |
|   STAGE 1: Technical Dossier Assembly & Gap Analysis                               |
|   Compile material characterization, ISO 10993 reports, or validation files.       |
|                                                                                    |
|   STAGE 2: Admin Formatting & eCOPY Submission                                     |
|   Prepare Cover Letter, Admin Details, Technical Sections, and submit via Gateway.  |
|                                                                                    |
|   STAGE 3: FDA Receipt & MAF Number Assignment                                     |
|   FDA DCC issues formal acknowledgment letter with assigned MAF-XXXXX number.     |
|                                                                                    |
|   STAGE 4: Commercial LOA Distribution & Premarket Support                          |
|   Issue signed LOAs to OEM clients referencing the assigned MAF-XXXXX number.      |
|                                                                                    |
|   STAGE 5: Annual Updates & Holder Amendments                                      |
|   Amend the file with FDA CDRH before material/process changes and keep it referenced. |
+------------------------------------------------------------------------------------+

Stage 1: Structuring the MAF Dossier

An MAF dossier should be organized logically using standardized regulatory section headings. CDRH recommends structuring the file into administrative and technical volumes:

1. Cover Letter & Administrative Volume:

   • MAF Holder name, physical address, DUNS number, and FDA Establishment Identifier (FEI).
   • Designated US Agent details (mandatory for foreign suppliers filing an MAF).
   • Statement of commitment to maintain the file and amend it before changes.
   • Identification of the MAF's functional scope (facilities, materials, packaging, sterilization, nonclinical, or clinical data).

2. Technical Volume:

   • Product / Material Description: Trade names, grade numbers, chemical structures, molecular weight distribution, CAS numbers.
   • Manufacturing & Process Description: Detailed flowcharts, solvent synthesis steps, catalyst residues, compounding parameters.
   • Quality Control & Specifications: Raw material certificate of analysis (CoA) release criteria, acceptance limits, test methods.
   • Validation & Safety Testing: Biocompatibility test reports (ISO 10993), extractable/leachable testing, stability protocols, sterilization validation data.

Stage 2: Submitting to FDA CDRH Document Control Center

MAFs must be submitted electronically to CDRH via the FDA Electronic Submissions Gateway (ESG) or on physical media adhering to FDA's eCOPY guidelines:

• Submission Address: Center for Devices and Radiological Health, Document Control Center (DCC), WO66-G609, 10903 New Hampshire Avenue, Silver Spring, MD 20993-0002.
• eCOPY Validation: Electronic files must pass FDA eCOPY PDF formatting rules (searchable text, embedded fonts, fast web view, no password protection).

Stage 3: Maintenance, Amendments, and the 5-Year Reference Rule (21 CFR § 814.20(c))

Filing an MAF is not a one-time event. Two binding obligations keep a master file usable:

1. The 5-year reference rule (21 CFR 814.20(c)): "If a master file is not referenced within 5 years after the date that it is submitted to FDA, FDA will return the master file to the person who submitted it." A holder whose MAF is not cross-referenced by any sponsor submission for five years effectively loses its active MAF.
2. Amend before changes (FDA MAF guidance): FDA's Device Master Files page is explicit that product or manufacturing changes can affect a client's cleared device, so the holder must amend the MAF and notify affected clients before implementing changes, not after.

+-----------------------------------------------------------------------------------+
|                MAF MAINTENANCE, AMENDMENT & REFERENCE RULES                        |
|                                                                                   |
|  1. AMEND BEFORE SUBSTANTIVE CHANGES:                                             |
|     - Submit an MAF amendment BEFORE changing material formulation or process.    |
|     - Notify all authorized OEM clients in writing of the pending change.         |
|     - Changes can trigger OEM re-evaluation under QMS supplier control.           |
|                                                                                   |
|  2. KEEP THE FILE REFERENCED:                                                     |
|     - 21 CFR 814.20(c): an MAF not referenced within 5 years is returned.        |
|     - Maintain an active list of LOAs and the submissions each supports.          |
|                                                                                   |
|  3. MINOR UPDATES & WITHDRAWAL:                                                   |
|     - Amend the file when additional testing expands the data scope.              |
|     - If a holder discontinues a material or closes an MAF, notify FDA and all    |
|       authorized OEMs so they can plan alternate source qualification.            |
+-----------------------------------------------------------------------------------+

Warning to Suppliers: An MAF that has not been amended for current manufacturing reality — or that has gone unreferenced long enough to be returned under 21 CFR 814.20(c) — cannot support a sponsor's submission. If an OEM submits a 510(k) or PMA referencing stale or missing MAF data, FDA reviewers will issue Additional Information (AI) or Refuse to Accept (RTA) deficiencies, halting the review clock until the holder amends and re-authorizes the file.

---

6. How MAFs Integrate with FDA eSTAR Submissions

Since October 2023, FDA CDRH has mandated the use of the electronic Submission Template and Resource (eSTAR) for all 510(k) submissions, extending eSTAR to De Novo requests and PMAs in subsequent phases.

Integrating an MAF into an eSTAR submission requires precise placement within the interactive PDF schema:

1. Section Selection: Navigate to the Supplier / Manufacturing Information or Biocompatibility / Sterilization sections in eSTAR.
2. Master File Identification: Select "Yes" when prompted whether raw materials, components, or sterilization cycles rely on a Master File.
3. Attachment of LOA: Upload the signed, supplier-provided LOA directly into the dedicated eSTAR attachment node.
4. Data Cross-Referencing: Input the exact MAF number, functional scope, and section numbers in the eSTAR text fields.

+------------------------------------------------------------------------------------+
|                         eSTAR MAF INTEGRATION CHECKLIST                            |
|                                                                                    |
|  [ ] Verify MAF Active Status with Supplier prior to eSTAR build.                   |
|  [ ] Confirm LOA explicitly names the exact OEM Legal Entity & Device Trade Name.   |
|  [ ] Ensure LOA covers the exact eSTAR submission type (510(k), PMA, De Novo).     |
|  [ ] Upload LOA PDF into eSTAR Node: "Biocompatibility -> Master File LOA".        |
|  [ ] Cross-check supplier component trade name in eSTAR against LOA text.           |
+------------------------------------------------------------------------------------+

For detailed guidance on structuring eSTAR packages and managing Additional Information (AI) responses, consult our companion guides on eSTAR submission templates and eSTAR AI response playbooks.

---

Recommended Reading

FDA Medical Device Advisory Committees: Panel Referral & Prep (2026)

Regulatory PMA2026-07-27 · 18 min read

7. Strategic Sourcing Playbook: Balancing IP Protection and Supply Chain Risk

For medical device OEM sourcing teams and regulatory managers, managing MAF-backed suppliers requires a balanced strategy that pairs IP protection with rigorous supply chain risk management.

Real-World Case Scenarios: MAF Deployment Across Medtech Sub-Sectors

To illustrate how MAFs function across different medical technology sectors, consider the following three operational case studies:

Scenario A: Bioabsorbable Polymer Resin Supplier (Materials MAF)

• Context: A chemical synthesis company develops a proprietary poly(L-lactide-co-caprolactone) (PLCL) bioabsorbable elastomer intended for cardiovascular scaffold coatings. The synthesis process involves proprietary organometallic catalysts and secret monomer ratios.
• MAF Execution: The supplier files a materials MAF with CDRH containing complete NMR spectroscopy, gel permeation chromatography (GPC), residual catalyst limits, and ISO 10993 biocompatibility reports.
• OEM Outcome: A stent manufacturer references the materials MAF in their PMA submission. FDA CDRH reviewers verify the polymer's safety directly within the MAF, while the stent manufacturer receives no access to the vendor's trade-secret catalyst recipe.

Scenario B: Contract Ethylene Oxide Sterilization Facility (Sterilization / Contract-Manufacturing MAF)

• Context: A contract sterilization company operates a network of multi-chamber EtO processing plants. They validate a standardized 100% EtO cycle with proprietary micro-vacuum pulses and low-temperature aeration profiles.
• MAF Execution: The sterilizer files a sterilization/contract-manufacturing MAF detailing cycle parameters, biological indicator (Geobacillus stearothermophilus) lethality curves, and chamber heat distribution maps under ISO 11135 guidelines.
• OEM Outcome: A disposable catheter manufacturer referencing the sterilization MAF avoids having to fund individual chamber qualification runs, cutting 12 weeks off their 510(k) preparation timeline.

Scenario C: AI SaMD Algorithm Licensing Vendor (Clinical-Data / Software MAF)

• Context: A digital health startup develops a proprietary deep-learning algorithm module for detecting cardiac arrhythmias from raw ECG waveforms. They license the software module to multiple patient monitor OEMs.
• MAF Execution: The software vendor files a clinical-data/software MAF with CDRH containing proprietary neural network architecture diagrams, training dataset demographic breakdowns, algorithm verification/validation (V&V) test cases, and IEC 62304 software documentation.
• OEM Outcome: Patient monitor manufacturers integrate the AI module into their hardware and reference the software MAF in their eSTAR 510(k) submissions, protecting the AI vendor's neural net code from exposure.

OEM Best Practices: Managing MAF Suppliers

1. Verify MAF Currency: Before signing commercial supply agreements or committing to a 510(k) predicate strategy, demand proof that the supplier's MAF is active with FDA CDRH (still within the 5-year reference window of 21 CFR 814.20(c)) and that it has been amended for current manufacturing.
2. Execute Robust Quality Agreements: An LOA permits FDA to view data, but it does not grant the OEM technical visibility. OEMs must execute formal supplier quality agreements requiring vendors to provide advance written notice (typically 90 to 180 days) prior to any material formulation change, site relocation, or MAF amendment.
3. Dual-Sourcing & Material Change Control: If a critical raw material vendor amends their materials MAF, the OEM must perform a change impact assessment under ISO 13485 / QMSR design control rules. Review our detailed guide on medical-grade resin change control and dual sourcing for risk mitigation strategies.
4. Establish Audit Rights: Ensure your supplier quality management program retains site audit rights for the supplier's facility, even if proprietary technical formulations remain locked inside the MAF.

---

8. FDA CDRH Deficiency Handling & Administrative Hold Resolution

During premarket review of an OEM's 510(k) or PMA, FDA reviewers may identify scientific gaps, missing characterization data, or outdated validation protocols within a referenced MAF. Because the MAF is confidential, resolving these deficiencies requires a specific administrative protocol:

+------------------------------------------------------------------------------------+
|                   MAF DEFICIENCY RESOLUTION & HOLD WORKFLOW                        |
|                                                                                    |
|  [Step 1: FDA Deficiency Identification]                                           |
|  FDA Lead Reviewer finds technical gap in MAF-XXXX during OEM 510(k) review.       |
|                                                                                    |
|  [Step 2: Dual Notification Protocol]                                              |
|  - FDA sends formal Deficiency Letter directly to MAF Holder detailing data gap.   |
|  - FDA notifies OEM Sponsor that 510(k) review is on hold due to MAF deficiencies  |
|    (without disclosing confidential MAF contents to the OEM).                      |
|                                                                                    |
|  [Step 3: Supplier Technical Amendment]                                            |
|  MAF Holder prepares technical response, testing, or revised specs and submits an  |
|  MAF Amendment via FDA Electronic Submissions Gateway (ESG).                       |
|                                                                                    |
|  [Step 4: FDA Re-Evaluation & Hold Release]                                        |
|  FDA Reviewer evaluates MAF Amendment, clears the deficiency, and resumes the      |
|  OEM 510(k) review clock.                                                          |
+------------------------------------------------------------------------------------+

Protocol Rules for OEM and Supplier Coordination

• OEM Actions: When FDA notifies an OEM that their submission is on hold due to MAF deficiencies, the OEM regulatory lead should immediately contact the MAF holder's regulatory contact, provide the FDA review division name and submission tracking number, and request confirmation that the supplier is actively addressing FDA's query.
• Supplier Actions: The MAF holder must submit the response as a formal MAF Amendment referencing the assigned MAF number. The cover letter must explicitly state that the amendment is submitted to resolve FDA deficiencies communicated regarding the specific OEM's premarket submission.

---

9. Global Regulatory Comparison: FDA MAFs vs. International Master File Frameworks

Medical device manufacturers expanding internationally must navigate varying regional approaches to supplier confidentiality and Master File acceptance.

Jurisdiction & Agency	Master File Framework	Supplier Data Confidentiality Mechanism	Key Differences vs. FDA CDRH MAF
United States (FDA CDRH)	Medical Device Master File (MAF)	Direct confidential submission under 21 CFR 814.20(c); access via Letter of Authorization (LOA).	Zero user fees; grouped by function (facilities, materials, packaging, sterilization, nonclinical, clinical); no public list published.
European Union (EU MDR / IVDR)	No General MAF Framework	Technical Documentation (Annex II/III) must be held by Legal Manufacturer; NBs require full data access.	No direct equivalent to MAF. Notified Bodies require OEMs to hold complete technical files. Suppliers must enter strict non-disclosure & tripartite audit agreements with NBs.
Health Canada (Medical Devices)	Device Master File (DMF)	Master File procedure for device components and raw materials; authorized via LOA.	Modeled closely after FDA MAFs; Health Canada accepts FDA MAF dossiers with Canadian administrative cover letters.
Japan (PMDA / MHLW)	Master File (MF) System	Master File registration system for medical device raw materials and components.	Mandatory registration system; PMDA assigns an MF registration number; annual maintenance fees apply.
Australia (TGA)	Device Master File / Category System	TGA accepts Master Files for active ingredients, raw materials, and sterilizer validations.	TGA aligns with Health Canada and FDA LOA mechanics; relies heavily on MDSAP audit reports.

---

Recommended Reading

FDA Safer Technologies Program (STeP) for Medical Devices: Complete Regulatory Guide

Regulatory 510(k)2026-07-24 · 20 min read

10. Frequently Asked Questions (FAQs)

Does FDA approve or clear a Medical Device Master File upon submission?

No. FDA CDRH does not approve, clear, or certify Master Files. FDA assigns an MAF reference number for administrative tracking and reviews the technical content only when an OEM cross-references the MAF in an active premarket submission (510(k), PMA, De Novo, IDE) backed by a valid Letter of Authorization (LOA).

Can a device sponsor view the confidential technical contents of an MAF?

No. An MAF is designed specifically to protect supplier trade secrets. A Letter of Authorization (LOA) authorizes FDA CDRH review staff to inspect the confidential file, but it gives the OEM sponsor no right to view or copy the supplier's proprietary data.

Are there FDA user fees for filing or maintaining a Medical Device Master File?

No. Unlike CDER Drug Master Files (DMFs) governed by GDUFA fees, CDRH Medical Device Master Files (MAFs) currently incur no FDA user fees for initial submission, LOA processing, or annual maintenance.

Does an MAF holder have to file annual reports with FDA?

FDA does not require a fixed annual report for device master files the way PMA holders must file PMA annual reports. The binding maintenance rule is different: under 21 CFR 814.20(c), FDA will return a master file to its holder if it is not referenced within 5 years of submission, and FDA's Device Master Files page requires the holder to amend the file and notify clients before making material or manufacturing changes. The practical risk is the same either way — if a sponsor references an MAF whose data is stale, amended away, or no longer on file, FDA will issue an AI or RTA deficiency and halt the review clock.

Can a foreign supplier file an MAF with FDA CDRH?

Yes. Foreign material suppliers, component vendors, and CMOs frequently file MAFs with FDA. Foreign submitters must designate an official United States Agent for Master File communications and submit all documentation in English or with certified English translations.

How does FDA handle MAFs for combination products?

For drug-device combination products, FDA assigns jurisdiction to CDRH or CDER based on the Primary Mode of Action (PMOA). If CDRH leads, device components use CDRH MAFs (21 CFR Part 814). If CDER leads, API and drug components use CDER DMFs (21 CFR § 314.420).

---

11. Regulatory & Source References

1. U.S. Code of Federal Regulations: eCFR 21 CFR 814.20(c) — incorporation by reference of a master file into a PMA (with "master file" defined at 21 CFR 814.3(d)), within 21 CFR Part 814 Subpart B (Premarket Approval Application).
2. FDA CDRH: Device Master Files — "Types of MAFs and Their Functions," "Amending an MAF," and "Authorization to an MAF" (content current December 6, 2023).
3. FDA CBER Guidance: Master Files for CBER-Regulated Products (Biologics and Cell/Gene Therapy Master Files).
4. FDA Scientific Guidance: Master Files Part III — Guidance on Scientific and Technical Information.
5. International Standards: ISO 13485:2016 — Medical devices — Quality management systems — Requirements for regulatory purposes (Clause 7.4 Purchasing & Supplier Control).